Comparison of efficacy and safety of 0.005% calcipotriol ointment versus 0.05% betamethasone dipropionate ointment versus calcipotriol plus betamethasone ointment for the treatment of vitiligo

Mahwish Zahoor, Shehla Shaukat, Muhammad Saleem Khan, Tahir Jamil Ahmad

Abstract


Objective To compare the efficacy and safety of calcipotriol ointment versus betamethasone ointment versus calcipotriol plus betamethasone ointment in patients of vitiligo.

 

Methods Patients with vitiligo (n=159) were randomized in three equal groups A, B and C. Group A (n=53) applied topical calcipotriol ointment, group B (n=53) applied topical betamethasone dipropionate ointment and group C (n=53) applied calcipotriol plus betamethasone ointment for a total of three months and were followed up for further 1 month. They were evaluated for improvement in pigmentation using Vitiligo Area Scoring Index (VASI) and side effects.

 

Results Out of a total of 159 patients, females (66.7%) out-numbered male patients (33.3%). Mean of change in VASI was 38.77 in group C, 26.23 in group B and 18.30 in group A. Overall change in VASI was highest in group C with a statistically significant p = 0.008. All the groups showed few side effects like erythema, burning, atrophy and acneiform eruption, which were not statistically significant.

 

Conclusion All topical therapies were found to be efficacious and safe in the treatment of vitiligo. But out of these three drugs, the combination of calcipotriol and betamethasone was superior in efficacy.

 


Keywords


Vitiligo, calcipotriol, betamethasone, VASI

Full Text:

PDF

References


Gonzalez U, Whitton M, Eleftheriadou V, Pinart M, Batchelor J, Leonardi-Bee J. Guidelines designing and reporting clinical trials in vitiligo. Arch Dermatol. 2011;147:1428-36.

Anstey AVP. Disorder of skin color. In: Burns T, Breathnach S, Cox N, Griffiths C, eds. Rook’s Textbook of Dermatology, 8th edn. Oxford, UK: Wiley-Blackwell Publishing; 2010. P.58.46-9.

Mahmoud BH, Hexsel CL, Hamzavi IH. An update on new and emerging options for the treatment of vitiligo. Skin Ther Lett. 2008;13(2):1-6.

Kawakami T, Hashimoto T. Disease severity index and treatment evaluation criteria in vitiligo. Dermatol Res Prac [Internet]. 2011. Available from: URL:http://www.hindawi.com/journals/dro/2011/750342

Falabella R, Barona MI. Update on skin repigmentation therapies in vitiligo. Pigment Cell Melanoma Res. 2009;22:42-65.

Vitiligo. [Internet] online. Available from: URL:http://www.bad.org.uk/site/885/default/.aspx.

Betamethasone. [Internet] online Wikipedia, the free encyclopedia. Available from: URL:http://en.m.wikipedia.org/wiki/Betamethasone.

Saldanha KD, Machado Filho CD, Paschoal FM. Action of topical mometasone on the pigmented halos of micrografting in patients with vitiligo. An Bras Dermatol. 2012;87:685-90.

Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol. 2006;20:269-73.

Mythili G, Sarma KLAP. Design and development of an area estimating system to find the body surface area affected by vitiligo using simulation approach. Int J Adv Res Comp Sci Sof Eng. 2012;2(3):75-81.

Alam MN, Wahab MA, Khondker L, Khan MSI. Comparative efficacy and safety of the combination of betamethasone dipropionate and calcipotriene with topical betamethasone dipropionate and calcipotriene alone in the treatment of localized vitiligo. J Pak Assoc Dermatol. 2014;24:143-9.

Xing C, Xu A. The effect of combined calcipotriol and betamethasone dipropionate ointment in the treatment of vitiligo: an open, uncontrolled trial. J Drugs Dermatol. 2012;11:52-4.

Aradhya SS, Manjunath K, Kasturi, Somiah KS. Quality of life and psychosocial impact of vitiligo in Indian patients. Pigment Int. 2015;2:28-33.


Refbacks

  • There are currently no refbacks.


ISSN: 1560-9014